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Ethics, AIDS, and Africa – three concepts that conjure up
a host of powerful associations. Ethics: our fragile human
attempts to negotiate acceptable paths through conflicts
of value. AIDS: the world's deadliest epidemic since the
Black Plague of the 14th century. And Africa: cradle of
humankind, burdened by colonization, famine, poverty
and civil war. In what ways do ethics, AIDS and Africa go
together, and how is our thinking challenged by their rela-
tionship?
Editors Van Niekerk and Kopelman have assembled an
impressive list of well-respected authors to deal with this
question. Their contributions focus on the impact of AIDS
in sub-Saharan Africa and take on some of the key ethical
issues raised by HIV/AIDS research, policy and clinical
practice in the region. Although rich in details, it is fair to
say that four general themes dominate this book: the eth-
ical role of national governments in tackling the AIDS epi-
demic, with special focus on the South African case; the
epidemic and responses to it as reflections of global ineq-
uity; the ethical responsibilities of pharmaceutical compa-
nies in the struggle against HIV/AIDS, and the dilemmas
involved in HIV prevention research, particularly in vac-
cine studies.
For a book on ethics, there is an unusual amount of agree-
ment. None of the authors seriously doubts the terrifying
social impact HIV/AIDS is currently having in sub-Saha-
ran Africa. There is general condemnation of the lack of
leadership and intransigence of the South African govern-
ment in its approach to both rolling out AIDS treatment
and redoubling its HIV prevention efforts. There is also no
question among the contributors that poverty, lack of
education, gender inequality and inadequate health care
infrastructure both fuel the spread of the virus and limit
access to treatment, and that tackling the epidemic in
Africa is inseparable from larger economic, social, politi-
cal, human rights and development issues.
But there are also interesting cracks in the consensus.
Solomon Benatar argues that the AIDS epidemic in Africa
has exposed our world as fundamentally inequitable and
unstable, and little progress will be made unless current
international relations in politics and trade are rethought
and remade. Anton Van Niekerk counters that efforts in
low-resource countries should focus on what is doable in
the short-term, rather than a quixotic pursuit for global
reform, and he argues that national governments in Africa
cannot be mere passive beneficiaries of international
funding – they have an ethical duty to create policies and
programs that sustain global AIDS initiatives. David Res-
nik claims that pharmaceutical companies have ethical
responsibilities towards those suffering from AIDS in the
developing world, but given the money-making impera-
tives of big pharma, this responsibility can only realisti-
cally take the form of some investment in R&D in the
developing world, discounts on drug prices or drug give-
aways. For Richard Ashcroft and Udo Schuklenk, such
'charity' on the part of multinational corporations is sim-
ply not good enough. When a country is experiencing a
devastating public health crisis, compulsory licensing of
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essential AIDS treatment may be the most effective and
ethically justified way of getting medication to those who
need it. In this way, Ashcroft and Schuklenk provide the
activist slogan "Patients before patents" with a deeper
philosophical justification.
Kevin De Cock, WHO's Director of the Department of
HIV/AIDS, recently stated at the last International AIDS
Conference in Toronto that 'we cannot treat our way out
of this epidemic.' HIV prevention research and policies are
crucial: the former to find novel ways of preventing new
infections, and the latter to channel prevention strategies
into practice. The chapters by Keymanthri Moodley, God-
frey Tangwa and Melissa Stobie et. al. offer an excellent
overview of the ethical and cultural issues encountered in
conducting HIV vaccine research in sub-Saharan Africa
with adults and children. Both Tangwa and Moodley tan-
talizingly claim that the informed consent process – cor-
nerstone of the ethical conduct of biomedical research in
the West – inappropriately assumes that the African
research participant can be separated from his kinship and
community ties. What would count as a more 'culturally
sensitive' consent process, however, remains elusive. Sto-
bie et. al. usefully discuss the tensions between ethical
concerns for individuals and concern for social groups in
HIV vaccine research. On the one hand, it would be in the
best interest of children as a class for there to be an effica-
cious HIV vaccine, at least for children growing up in a
high HIV prevalence setting. But it may or may not be in
an individual child's best interest to participate in an HIV
vaccine trial. The discussion of the deep ambiguities in
South African laws and guidelines concerning the best
interests of children, the limits of parental consent to
research involving children and the determination of risk
in pediatric studies is both illuminating and sobering. It is
not as if laws and guidance on pediatric research are much
clearer elsewhere.
There are some minor limitations to this book. Although
the title refers to Africa, the focus is really on sub-Saharan
Africa, with a special emphasis on South Africa. To a cer-
tain extent, this is understandable and justified. South
Africa has an estimated 5.5 million persons living with
HIV and approximately 1000 persons dying of AIDS daily.
The South Africa government is a reliable source of bizarre
HIV-related publicity, be it the President's embrace of
rogue scientists who deny HIV causes AIDS, a health min-
ister who suggests garlic and nutritional supplements are
as effective as anti-retrovirals in controlling AIDS, or a pre-
vious head of the South African AIDS Council who claims
a post-coital shower (after sex with an HIV positive
woman) can protect him against the virus. South Africa
also, as it turns out, has exceptional centers for bioethics
and research ethics at Cape Town and Pretoria. Neverthe-
less, the book might have profited by looking farther
afield and incorporating voices of West and East Africans,
and Africans living above the Sahara.
Many of the pieces in the book seem to have been origi-
nally written around 2001, and therefore the factual data
and the ethical commentary based on the data sometimes
appear a bit dated. The results of the efforts by the Global
Fund, PEPFAR, the Clinton Foundation and the Bill and
Melinda Gates Foundation over the last five years are not
well-represented. HIV prevention research is currently
focused on more on female-controlled methods (microbi-
cides) and controversial surgical interventions (male cir-
cumcision) as the development of an effective vaccine still
seems a lot way off. Keeping the ethics up to date is clearly
a difficult task, given the rapid evolution in disease
dynamics and in the political, economic and scientific
responses to the HIV/AIDS epidemic.
These minor reservations aside, Ethics and AIDS in Africa
is a highly illuminating, stimulating and informative
guide to the ethical dilemmas faced by researchers, policy-
makers and health care providers in the countries hardest
hit by HIV/AIDS. The book clearly delivers on its promise
that HIV/AIDS, as it continues to ravage low-resource
countries of Africa, challenges everyone's ethical thinking.